196 completed, 54 terminated, 41 recruiting, 37 unknown. 142 Not applicable, 103 Phase 2, 49 Phase 1, 21 Phase 3, 21 Phase 4.
Follow Georgetown University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation - Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | Not yet recruiting | Georgetown University | 108 | 2026-12-01 | 2026-10-06 |
| The INTERvening for LUNG Health Trial Community health worker-delivered multi-component respiratory health intervention - Spirometry | Phase 4 | Not yet recruiting | Johns Hopkins University | 800 | 2026-11-15 | 2026-10-08 |
| SBRT for Ultra-Central NonSmall Cell Lung Cancer SBRT - Nonsmall Cell Lung Cancer Stage | Phase 1 | Not yet recruiting | Georgetown University | 35 | 2026-11-01 | 2026-10-01 |
| Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features Cemiplimab-Rwlc - Non-small Cell Lung Cancer Stage III | Phase 2 | Recruiting | Georgetown University | 21 | 2026-11-01 | 2026-10-06 |
| RESvEraTrol in Parkinson's Disease (RESET) Trans-Resveratrol - Parkinson's Disease | Phase 2 | Recruiting | Georgetown University | 30 | 2026-09-17 | 2026-09-18 |
| MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer Microboost SBRT, Whole gland de-escalation 30 Gy, Whole gland de-escalation 35 Gy - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Georgetown University | 58 | 2026-09-01 | 2026-08-20 |
| A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients NY-ESO-1 Peptide vaccine, Toripalimab-tpzi - Ovarian Cancer Stage IV, Ovarian Cancer Stage III | Phase 2 | Withdrawn | Georgetown University | 2026-09-01 | 2026-10-09 | |
| Expanding Genetic Access for Prostate Cancer Survivors Print Genetic Education Guide, Digital Guide Genetic Education Guide, Enhanced Usual Care - Prostate Cancer Patients, Hereditary Cancer | Not applicable | Not yet recruiting | Georgetown University | 500 | 2026-08-01 | 2026-06-01 |
| Home-based Vision Rehabilitation Guided by Brain Imaging High-level perceptual learning-based training, Low-level perceptual learning-based training - Visual Field Defect, Stroke | Not applicable | Recruiting | Georgetown University | 100 | 2026-07-23 | 2026-09-14 |
| Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. Pre-radiation temozolomide. - High Grade Gliomas, Glioblastoma | Phase 2 | Recruiting | The Cooper Health System | 70 | 2026-07-13 | 2026-10-09 |
| Hard Cervical Collar Use Following Posterior Cervical Fusion Hard Cervical Collar - Spinal Stenosis Cervical, Radiculopathy, Cervical Region | Not applicable | Recruiting | Georgetown University | 150 | 2026-06-03 | 2026-10-01 |
| Bundled Cancer Screening and Genetic Services Navigation Breast cancer screening navigation, Multicancer screening navigation, Usual care genetics referral - Breast Cancer Screening, Colon Cancer Screening | Not applicable | Recruiting | Georgetown University | 820 | 2026-05-06 | 2026-05-08 |
| Dietary Intervention for Migraine Relief Dietary training - Migraine | Not applicable | Recruiting | American University | 40 | 2026-03-02 | 2026-10-30 |
| PathToScale: The PERSIST Trial Standard of Care (SoC), Enhanced continuation support package - Oral Pre-exposure Prophylaxis (PrEP), Long-acting Injectable Cabotegravir for PrEP | Not applicable | Recruiting | Georgetown University | 9900 | 2026-02-16 | 2026-03-04 |
| Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors Sleep Healthy Using the Internet (SHUTi), Patient education - Insomnia | Not applicable | Recruiting | Georgetown University | 40 | 2025-12-01 | 2026-10-26 |
| PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients) There is no required Intervention for this Protocol. Based on Results for TruGraf/TRAC/TRAC ID Investigators may use the results in managing subjects Immunosuppression or rule out rejection. - Immunosuppression Management, Biomarkers / Blood | Not yet recruiting | Transplant Genomics, Inc. | 600 | 2025-11-20 | 2025-11-17 | |
| Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients Radioactive Iodine Support (RAI Support), Treatment as Usual (TAU) - Thyroid Neoplasms | Not applicable | Recruiting | Georgetown University | 88 | 2025-10-02 | 2026-01-16 |
| Daratumumab for Polyneuropathy Associated With MGUS Daratumumab and hyaluronidase-fihj - Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Withdrawn | Georgetown University | 2025-09-26 | 2025-10-01 | |
| Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer Decision Aid, Usual Care - Thyroid Cancer | Not applicable | Recruiting | Georgetown University | 408 | 2025-08-06 | 2026-01-08 |
| Omega-3D: Omega-3 for Diet-Driven Health Disparities Omega-3 Fatty Acids and Safflower Oil Placebo, Safflower Oil Placebo and Omega-3 Fatty Acids - Heart Health Markers, Cardiovascular Diseases | Phase 2 | Recruiting | University of Arizona | 200 | 2025-07-31 | 2025-12-16 |
Showing 20 of 378. Sign in to see all of them.
Breast Neoplasms (43) · Pancreatic Neoplasms (15) · Prostatic Neoplasms (15) · Neoplasms (14) · Stroke (14) · Motor Activity (13) · Colorectal Neoplasms (10) · Lung Neoplasms (10) · Anxiety Disorders (8) · Neoplasm Metastasis (7) · Stress Disorders, Post-Traumatic (7) · Chronic Pain (6) · Cognitive Dysfunction (6) · Depression (6) · Diabetes Mellitus (6)
Bevacizumab (7) · Capecitabine (7) · Fluorouracil (7) · Gemcitabine (7) · Nivolumab (6) · Oxaliplatin (6) · Cisplatin (5) · Counseling (5) · Irinotecan (5) · Leucovorin (5) · Rituximab (5) · Standard of Care (5) · nilotinib (5) · pembrolizumab (5) · Cetuximab (4)
United States (342) · Bangladesh (2) · Canada (2) · Malawi (2) · Bolivia (1) · Democratic Republic of the Congo (1) · Estonia (1) · Israel (1) · Kenya (1) · Liberia (1) · Nepal (1) · Peru (1) · Philippines (1) · Rwanda (1) · Senegal (1)
Christopher Attinger, MD (7) · Michael Pishvaian, MD PhD (7) · Benjamin Weinberg, MD (6) · Claudine Isaacs, MD (6) · Daniel Merenstein, MD (6) · Chul Kim, MD (5) · Fernando L Pagan, MD (5) · James N Baraniuk, MD (5) · Darren Mays, PhD, MPH (4) · John L. Marshall, MD (4) · Candace Mainor, MD (3) · Jill P Smith, MD (3) · John L Marshall, MD (3) · John Marshall, MD (3) · John Steinberg, DPM (3)
PMID 23898301, PMID 24567288, PMID 27434297, PMID 28712102, PMID 29487023, PMID 29674668, PMID 33274349, PMID 40680102, PMID 12057784, PMID 17491171, PMID 18364345, PMID 18512816, PMID 19645031, PMID 19652108, PMID 19786427, PMID 19922923, PMID 20040569, PMID 20093899, PMID 20199680, PMID 20211945, PMID 20216564, PMID 20564682, PMID 20578178, PMID 20733447, PMID 21220660, PMID 21233468, PMID 21252632, PMID 21375763, PMID 21493789, PMID 21512751, PMID 21565525, PMID 21656058, PMID 21766553, PMID 21785892, PMID 21842404, PMID 21955465, PMID 22354616, PMID 22362158, PMID 22549748, PMID 22840291, PMID 22984337, PMID 23010696, PMID 23253653, PMID 23526988, PMID 23618477, PMID 23666528, PMID 23741991, PMID 23798990, PMID 23896732, PMID 24415903
P30CA051008 (14), R44DK068936 (3), P50CA058185 (2), R01CA082346 (2), R01CA108933 (2), R01CA207228 (2), R44NS125745 (2), U01DA029580 (2), U54NS057405 (2), 2008 (1), 4UH3DE031248-03 (1), 75N91020C00043-0-9999-1 (1), I01RX001783 (1), K01MH073814 (1), P20MH068450 (1)